Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.15EUR
−81.73 MEUR
42.98 M
About Terns Pharmaceuticals, Inc.
Sector
Industry
CEO
Amy L. Burroughs
Website
Headquarters
Foster City
Employees (FY)
66
Founded
2017
FIGI
BBG00ZSLM2G9
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange TERNS PHARMACEUT.DL-,0001 stocks are traded under the ticker 430.
We've gathered analysts' opinions on TERNS PHARMACEUT.DL-,0001 future price: according to them, 430 price has a max estimate of 20.24 EUR and a min estimate of 5.06 EUR. Watch 430 chart and read a more detailed TERNS PHARMACEUT.DL-,0001 stock forecast: see what analysts think of TERNS PHARMACEUT.DL-,0001 and suggest that you do with its stocks.
Yes, you can track TERNS PHARMACEUT.DL-,0001 financials in yearly and quarterly reports right on TradingView.
TERNS PHARMACEUT.DL-,0001 is going to release the next earnings report on Aug 6, 2024. Keep track of upcoming events with our Earnings Calendar.
430 earnings for the last quarter are −0.28 EUR per share, whereas the estimation was −0.32 EUR resulting in a 13.41% surprise. The estimated earnings for the next quarter are −0.31 EUR per share. See more details about TERNS PHARMACEUT.DL-,0001 earnings.
TERNS PHARMACEUT.DL-,0001 revenue for the last quarter amounts to 0 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
430 net income for the last quarter is −20.73 M EUR, while the quarter before that showed −19.04 M EUR of net income which accounts for −8.88% change. Track more TERNS PHARMACEUT.DL-,0001 financial stats to get the full picture.
No, 430 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 15, 2024, the company has 66.00 employees. See our rating of the largest employees — is TERNS PHARMACEUT.DL-,0001 on this list?
Like other stocks, 430 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TERNS PHARMACEUT.DL-,0001 stock right from TradingView charts — choose your broker and connect to your account.